HPV-vaccin (9-valente vaccin) biedt ook bescherming tegen HPV-gerelateerde kankers bij tieners en jonge volwassen mannen blijkt uit studie onder 615.155 gevaccineerde en 2.290.623 ongevaccineerde mannen in de leeftijd van 9 tot 26 jaar

Zie ook onze disclaimer.

Zie ook in gerelateerde artiekelen.

Zie ook website Vereniging Kritisch Prikken

23 juni 2026: Bron: JAMA d.d. 1 juni 2026

Een prospectieve studie onder 615.155 gevaccineerde en 2.290.623 ongevaccineerde mannen in de leeftijd van 9 tot 26 jaar toonde aan dat mannen die gevaccineerd waren met GARDASIL 9, het 9-valente HPV-vaccin een lager risico hadden op HPV-gerelateerde kanker (bij mannen zijn dat mond- en keelkanker, slokdarmkanker, peniskanker en anuskanker ) in vergelijking met de ongevaccineerde groep. Het negatieve verband tussen het GARDASIL 9, het 9-valente HPV-vaccin en HPV-gerelateerde kanker bleef bestaan bij zowel tieners van 9 tot 14 jaar als jongens/mannen van 15 tot 26 jaar.

Uit het abstract vrij vertaald en aangevuld met extra informatie:

Vóór de propensity score matching werden in de VS 615.155 gevaccineerde mannen (gemiddelde leeftijd, 13,4 jaar) en 2.290.623 ongevaccineerde mannen (gemiddelde leeftijd, 17,2 geïdentificeerd.
Na de propensity score matching werden in elke groep 510.260 deelnemers opgenomen.
Vergeleken met de ongevaccineerde groep hadden de gevaccineerde deelnemers een lager risico op de primaire samengestelde uitkomst. (red.: minder kans op het krijgen van mond- en keelkanker, slokdarmkanker, peniskanker en anuskanker)
Subgroepanalyse toonde aan dat de significant lagere incidentie van de primaire samengestelde uitkomst in de gevaccineerde groep behouden bleef bij zowel jongens van 9 tot 14 jaar (HR, 0,58; 95% CI, 0,34-0,97; P = 0,04) als jongens/mannen van 15 tot 26 jaar.

(Redactie: De propensity score is het resultaat van een multivariate logistische regressieanalyse van een verzameling van confounders en drukt de kans uit dat iemand heeft om op basis van deze confounders al dan niet behandeld te worden. Als we in een observationele studie twee groepen matchen voor de propensity score schakelen we veel confounders uit zonder groot verlies aan observaties.)

Of het verstandig is je zoontje te laten vaccineren heb ik persoonlijk grote twijfels gezien de kans op bijwerkingen op langere termijn van het GARDASIL 9, het 9-valente HPV-vaccin nog steeds niet goed zijn onderzocht. Bovendien is het verhoudingsgewijs duur om je te laten vaccineren, al wordt GARDASIL 9, het 9-valente HPV-vaccin vanaf 1 september 2026 vergoed vanuit de basisverzekering. Zie RIVM.

Het studieveerslag is gepubliceerd in JAMA d.d. 1 juni 2026:

Key Points

Question Is the 9-valent human papillomavirus (9v-HPV) vaccine associated with lower risk of cancer in males?

Findings This cohort study of 615 155 vaccinated and 2 290 623 unvaccinated males aged 9 to 26 years found that males vaccinated with the 9v-HPV vaccine had a lower risk of HPV-related cancer compared with the unvaccinated cohort. The negative association of the 9v-HPV vaccine with HPV-related cancer was maintained in both males aged 9 to 14 years and males aged 15 to 26 years.

Meaning The findings of this study suggest that the 9v-HPV vaccine is beneficial not only for females but also for males.

Abstract

Importance The disease burden of human papillomavirus (HPV)–related cancers is substantial, irrespective of sex. Establishing evidence on the effectiveness of the 9-valent HPV vaccine for males may support the implementation of sex-neutral HPV vaccination strategies.

Objective To evaluate the incidence of HPV-related cancers between 9-valent HPV-vaccinated and unvaccinated males using a large-scale database.

Design, Setting, and Participants This multicenter retrospective cohort study utilized a global database. Participants included males aged 9 to 26 years who were either unvaccinated or received at least one 9-valent HPV vaccine between January 2016 and December 2024 with outcomes followed-up for up to 10 years.

Main Outcomes and Measures The primary composite outcomes were HPV-related cancers, including head and neck, esophageal, anal, and penile cancers. Hazard ratios (HRs) were estimated using propensity score matching.

Results Before propensity score matching, 615 155 vaccinated males (mean age, 13.4 [3.5] years) and 2 290 623 unvaccinated males (mean age, 17.2 [5.5] years) were identified in the US. After propensity score matching, 510 260 participants were included in each group. Compared with those in the unvaccinated group, those in the vaccinated group had a lower risk of the primary composite outcome (HR, 0.54; 95% CI, 0.37-0.81; P = .002). Subgroup analysis demonstrated that the significantly lower incidence of the primary composite outcome in the vaccinated group was maintained among both males aged 9 to 14 years (HR, 0.58; 95% CI, 0.34-0.97; P = .04) and those aged 15 to 26 years (HR, 0.50; 95% CI, 0.27-0.93; P = .03).

Conclusions and Relevance This study found a significant negative association of the 9-valent HPV vaccine with HPV-related cancers in adolescents and young adult males and contributes to the development of sex-neutral HPV vaccination.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Kitano reported receiving grants from BioMérieux outside the submitted work. Dr Yoshida reported receiving grants from TAUNS Laboratories and Mizuho Medy outside the submitted work.

Cited by

The news is not all bad: five inspiring science stories to lift your mood.
Fieldhouse R.Nature. 2026 May 1. doi: 10.1038/d41586-026-01290-5. Online ahead of print.PMID: 42067600No abstract available.

References

1. Rahangdale L, Mungo C, O’Connor S, Chibwesha CJ, Brewer NT. Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022;379:e070115. doi: 10.1136/bmj-2022-070115 - DOI - PubMed
1. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180-e190. doi: 10.1016/S2214-109X(19)30488-7 - DOI - PubMed
1. Syrjänen S. The role of human papillomavirus infection in head and neck cancers. Ann Oncol. 2010;21(suppl 7):vii243-vii245. doi: 10.1093/annonc/mdq454 - DOI - PubMed
1. McDonald SA, Qendri V, Berkhof J, de Melker HE, Bogaards JA. Disease burden of human papillomavirus infection in the Netherlands, 1989-2014: the gap between females and males is diminishing. Cancer Causes Control. 2017;28(3):203-214. doi: 10.1007/s10552-017-0870-6 - DOI - PubMed
1. Savoy M; FAAFP; FABC; CPE; CMQ; FAAPL . Vaccination is the most effective strategy for HPV prevention. Dela J Public Health. 2019;5(2):18-19. doi: 10.32481/djph.2019.05.005 - DOI - PMC - PubMed
1. Wu S, Ploner A, Astorga Alsina AM, Deng Y, Ask Schollin L, Lei J. Effectiveness of quadrivalent human papillomavirus vaccination against high-grade cervical lesions by age and doses: a population-based cohort study. Lancet Reg Health Eur. 2025;49:101178. doi: 10.1016/j.lanepe.2024.101178 - DOI - PMC - PubMed
1. Hung YM, Lin TT, Wang SI, Wu PJ, Chang R, Wei JC. HPV vaccination is associated with lower risk of cancers among females. Am J Med. 2025; 139(3):311-320.e12. doi: 10.1016/j.amjmed.2025.10.016 - DOI - PubMed
1. Bergman H, Henschke N, Arevalo-Rodriguez I, et al. Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis. Cochrane Database Syst Rev. 2025;11(11):CD015364. doi: 10.1002/14651858.CD015364.pub2 - DOI - PMC - PubMed
1. Henschke N, Bergman H, Buckley BS, et al. Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination. Cochrane Database Syst Rev. 2025;11(11):CD015363. doi: 10.1002/14651858.CD015363.pub2 - DOI - PMC - PubMed
1. Guo F, Chang M, Scholl M, McKinnon B, Berenson AB. Trends in oropharyngeal cancer incidence among adult men and women in the United States from 2001 to 2018. Front Oncol. 2022;12:926555. doi: 10.3389/fonc.2022.926555 - DOI - PMC - PubMed
1. Restivo V, Minutolo G, Maranto M, et al. Impact of preventive strategies on HPV-related diseases: ten-year data from the Italian Hospital Admission Registry. Cancers (Basel). 2023;15(5):1452. doi: 10.3390/cancers15051452 - DOI - PMC - PubMed
1. Alessandrini J, Cox J, de Pokomandy A, et al. ; Engage-HPV Team . Prevalence of oral human papillomavirus infection among urban gay, bisexual, and other men who have sex with men in Canada, 2017-2019. J Infect Dis. 2024;230(5):e1039-e1048. doi: 10.1093/infdis/jiae345 - DOI - PMC - PubMed
1. Han J, Zhang L, Chen Y, et al. Global HPV vaccination programs and coverage rates: a systematic review. EClinicalMedicine. 2025;84:103290. doi: 10.1016/j.eclinm.2025.103290 - DOI - PMC - PubMed
1. Signorelli C, Odone A, Ciorba V, et al. Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. Epidemiol Infect. 2017;145(10):1962-1982. doi: 10.1017/S0950268817000747 - DOI - PMC - PubMed
1. Miazga W, Tatara T, Gujski M, Pinkas J, Ostrowski J, Religioni U. Global guidelines and trends in HPV vaccination for cervical cancer prevention. Med Sci Monit. 2025;31:e947173. doi: 10.12659/MSM.947173 - DOI - PMC - PubMed
1. Malvolti S, Soble A, Bloem P, et al. The Global demand and supply balance of the human papillomavirus vaccine: implications for the global strategy for the elimination of cervical cancer. Vaccines (Basel). 2023;12(1):4. doi: 10.3390/vaccines12010004 - DOI - PMC - PubMed
1. Ludwig RJ, Anson M, Zirpel H, et al. A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. Front Pharmacol. 2025;16:1516126. doi: 10.3389/fphar.2025.1516126 - DOI - PMC - PubMed
1. Ellingson MK, Sheikha H, Nyhan K, Oliveira CR, Niccolai LM. Human papillomavirus vaccine effectiveness by age at vaccination: a systematic review. Hum Vaccin Immunother. 2023;19(2):2239085. doi: 10.1080/21645515.2023.2239085 - DOI - PMC - PubMed
1. Boitano TKL, Ketch PW, Scarinci IC, Huh WK. An update on human papillomavirus vaccination in the United States. Obstet Gynecol. 2023;141(2):324-330. doi: 10.1097/AOG.0000000000005056 - DOI - PMC - PubMed
1. Jensen JE, Becker GL, Jackson JB, Rysavy MB. Human papillomavirus and associated cancers: a review. Viruses. 2024;16(5):680. doi: 10.3390/v16050680 - DOI - PMC - PubMed
1. Stein E, Hüser M, Amirian ES, Palchuk MB, Brown JS. TriNetX Dataworks-USA: overview of a multi-purpose, de-identified, federated electronic health record real-world data and analytics network and comparison to the US census. Pharmacoepidemiol Drug Saf. 2025;34(9):e70198. doi: 10.1002/pds.70198 - DOI - PMC - PubMed
1. Olaker VR, Fry S, Terebuh P, et al. With big data comes big responsibility: strategies for utilizing aggregated, standardized, de-identified electronic health record data for research. Clin Transl Sci. 2025;18(1):e70093. doi: 10.1111/cts.70093 - DOI - PMC - PubMed
1. Dhull AK, Atri R, Dhankhar R, Chauhan AK, Kaushal V. Major risk factors in head and neck cancer: a retrospective analysis of 12-year experiences. World J Oncol. 2018;9(3):80-84. doi: 10.14740/wjon1104w - DOI - PMC - PubMed
1. English KJ. Anal carcinoma—exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment. World J Exp Med. 2024;14(3):98525. doi: 10.5493/wjem.v14.i3.98525 - DOI - PMC - PubMed
1. Brenne SS, Ness-Jensen E, Edna TH, Lydersen S, Laugsand EA. Risk factors for right colon, left colon and rectal cancers differ between men and women: the population-based HUNT study in Norway. Colorectal Dis. 2023;25(1):44-55. doi: 10.1111/codi.16324 - DOI - PMC - PubMed
1. Douglawi A, Masterson TA. Penile cancer epidemiology and risk factors: a contemporary review. Curr Opin Urol. 2019;29(2):145-149. doi: 10.1097/MOU.0000000000000581 - DOI - PubMed
1. Rosado C, Fernandes ÂR, Rodrigues AG, Lisboa C. Impact of human papillomavirus vaccination on male disease: a systematic review. Vaccines (Basel). 2023;11(6):1083. doi: 10.3390/vaccines11061083 - DOI - PMC - PubMed
1. Lipsky MS, Gunnell B, Nguyen J, Lee S, Wolfe G, Hung M. HPV prevention in men: a narrative review of strategies, risks, and public health implications. Am J Mens Health. 2025;19(6):15579883251391750. doi: 10.1177/15579883251391750 - DOI - PMC - PubMed
1. Tan T, Li S, Bai C, et al. Prevalence and risk factors of high-risk sexual behavior among elderly men with HIV infection in Chongqing, China. Sci Rep. 2025;15(1):8053. doi: 10.1038/s41598-025-92661-x - DOI - PMC - PubMed
1. Silan V, Kant S, Haldar P, Goswami K, Rai SK, Misra P. HIV risk behavior among men who have sex with men. N Am J Med Sci. 2013;5(9):515-522. doi: 10.4103/1947-2714.118931 - DOI - PMC - PubMed
1. Choi Y, Eworuke E, Segal R. What explains the different rates of human papillomavirus vaccination among adolescent males and females in the United States? Papillomavirus Res. 2016;2:46-51. doi: 10.1016/j.pvr.2016.02.001 - DOI - PMC - PubMed
1. United States Centers for Disease Prevention and Control. Advisory Committee on Immunization Practices (ACIP) . Evidence to recommendations for HPV vaccination harmonization across sexes, ages 22 through 26 years. Published September 5, 2024. Accessed December 26, 2025. https://www.cdc.gov/acip/evidence-to-recommendations/HPV-harmonization-e...
1. United Kingdom Health Security Agency . HPV vaccination guidance for healthcare practitioners. Updated 20 June 2023. Accessed December 26, 2025. https://www.gov.uk/government/publications/hpv-universal-vaccination-gui...
1. Prem K, Cernuschi T, Malvolti S, Brisson M, Jit M. Optimal human papillomavirus vaccination strategies in the context of vaccine supply constraints in 100 countries. EClinicalMedicine. 2024;74:102735. doi: 10.1016/j.eclinm.2024.102735 - DOI - PMC - PubMed
1. Dykens JA, Peterson CE, Holt HK, Harper DM. Gender neutral HPV vaccination programs: reconsidering policies to expand cancer prevention globally. Front Public Health. 2023;11:1067299. doi: 10.3389/fpubh.2023.1067299 - DOI - PMC - PubMed
1. Cherif A, Palmer C, Senese F, et al. A cost-effectiveness analysis of adult human papillomavirus vaccination strategies in Italy. Hum Vaccin Immunother. 2025;21(1):2474891. doi: 10.1080/21645515.2025.2474891 - DOI - PMC - PubMed
1. La Rosa A, Verdoux M, Riebler P, et al. Multimodal identification of a rare head and neck cancer patient cohort in the clinical data warehouse of Greater Paris Teaching Hospital. ESMO Real World Data Digit Oncol. Published online May 29, 2025. doi: 10.1016/j.esmorw.2025.100151 - DOI
1. National Cancer Institute . Surveillance research program, SEER explorer: an interactive website for SEER cancer statistics. Published April 16, 2025. Updated January 8, 2026. Accessed on February 12, 2026. https://seer.cancer.gov/statistics-network/explorer/
1. QuickStats . QuickStats: percentage* of children† aged <18 years who received a well-child checkup in the past 12 months,§ by age group and year—National Health Interview Survey, United States, 2008 and 2018¶. MMWR Morb Mortal Wkly Rep. 2020;69(8):222. doi: 10.15585/mmwr.mm6908a5 - DOI - PMC - PubMed
1. Hirth J. Disparities in HPV vaccination rates and HPV prevalence in the United States: a review of the literature. Hum Vaccin Immunother. 2019;15(1):146-155. doi: 10.1080/21645515.2018.1512453 - DOI - PMC - PubMed
1. Pingali C, Yankey D, Elam-Evans LD, et al. Vaccination coverage among adolescents aged 13-17 Years—National Immunization Survey-Teen, United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(30):466-472. doi: 10.15585/mmwr.mm7430a1 - DOI - PMC - PubMed
1. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-475. doi: 10.1158/1055-9965.EPI-04-0551 - DOI - PubMed
1. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010;2:15. doi: 10.1186/1758-3284-2-15 - DOI - PMC - PubMed
1. Vani NV, Rama R, Madhanagopal R, Vijayalakshmi R, Swaminathan R. Human papillomavirus-attributable head and neck cancers in India-a systematic review and meta-analysis. JCO Glob Oncol. 2024;10:e2300464. doi: 10.1200/GO.23.00464 - DOI - PMC - PubMed
1. Tota JE, Best AF, Zumsteg ZS, Gillison ML, Rosenberg PS, Chaturvedi AK. Evolution of the oropharynx cancer epidemic in the United States: moderation of increasing incidence in younger individuals and shift in the burden to older individuals. J Clin Oncol. 2019;37(18):1538-1546. doi: 10.1200/JCO.19.00370 - DOI - PMC - PubMed